AbbVie Nears Deal to Buy Allergan for More Than $60 Billion
June 25 2019 - 6:56AM
Dow Jones News
By Cara Lombardo, Jonathan D. Rockoff and Dana Cimilluca
AbbVie Inc. is nearing a deal to buy Allergan PLC for more than
$60 billion, according to people familiar with the matter, as the
two big drugmakers bet a combination will deliver new sources of
growth they have struggled to find on their own.
The takeover, worth $188 a share in cash and stock, is expected
to be announced later Tuesday, the people said. The price, mainly
to be paid in cash, represents a 45% premium over Allergan's
closing share price Monday of $129.57. If not for a surge in the
shares in recent days on expectations for a breakup of the company,
the premium would be even bigger.
Buying Dublin-based Allergan would deliver a dominant position
in the $8 billion-plus market for Botox and other beauty drugs, as
well as a number of popular eye treatments, as AbbVie braces for
the end of patent protection for the world's top-selling drug,
Humira.
The companies' portfolios have some overlap in treatments for
brain, women's-health, stomach and other disorders, though the
combination would take AbbVie into the new realm of frown-line
smoothing, eyelash lengthening and double-chin removal.
Allergan's nearly $16 billion in yearly revenue would also give
AbbVie another source of cash to hunt for a new generation of
products.
(END) Dow Jones Newswires
June 25, 2019 06:41 ET (10:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Sep 2023 to Sep 2024